Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Actavis, Inc. (ACT - Analyst Report) recently launched its generic version of Endo Health Solutions' (ENDP - Analyst Report) Lidoderm (lidocaine topical patch 5%). Actavis’ generic version was launched under an exclusive settlement agreement with Endo and and Teikoku Seiyaku Co., Ltd. The companies had entered into a settlement agreement in May 2012.

Lidoderm is used for the relief of post-shingles pain and generated U.S. sales of $1.4 billion for the twelve months ending May 31, 2013, as per IMS Health Data. The generic Lidoderm launch is an important launch for the company  - Actavis believes it is entitled to 180-days exclusivity under the Hatch Waxman Act.

Actavis launched its generic version of another product as well – Endo’s Opana ER (oxymorphone hydrochloride extended-release tablets, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg). The company had gained FDA approval for these dosages in Jul 2013. We note that Actavis was already marketing its generic version of the 7.5 mg and 15 mg dosage strengths of Opana ER.

Opana ER, an opioid agonist, is approved for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. According to IMS Health, Opana ER sales in the U.S. for the 12 months ended May 31, 2013, were about $461 million.

Currently, Actavis is facing a patent infringement lawsuit regarding the sale of its generic versions of Opana ER.

Actavis is a Zacks Rank #2 (Buy) stock. Earlier this year, Actavis had announced its intention to acquire Warner Chilcott . We are positive on this deal which makes strategic and financial sense. The deal, which is scheduled to close early in the fourth quarter, is expected to be immediately accretive. Moreover, it will provide strong operating cash flow and allow Actavis to de-lever its balance sheet. The tax rate will also be significantly below current levels.

Other companies doing well include Supernus Pharmaceuticals, Inc. (SUPN - Snapshot Report), a Zacks Rank #1 (Strong Buy) stock.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%